ACLX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -308.4% compared to Arcellx's net margin of --. Arcellx's return on equity of -22.3% beat Perspective Therapeutics's return on equity of --.

Arcellx has a consensus price target of $115.40, signalling upside risk potential of 95.1%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than Arcellx, analysts believe Perspective Therapeutics is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $15.3M, which are larger than Perspective Therapeutics quarterly revenues of --. Arcellx's net income of -$47.1M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, Arcellx's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 29.35x versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -308.4% compared to Arcellx's net margin of -49.65%. Arcellx's return on equity of -22.3% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Arcellx has a consensus price target of $115.40, signalling upside risk potential of 95.1%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Arcellx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Arcellx is more attractive than NovaBay Pharmaceuticals.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $15.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcellx's net income of -$47.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Arcellx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 29.35x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -308.4% compared to Arcellx's net margin of -2357.27%. Arcellx's return on equity of -22.3% beat Palatin Technologies's return on equity of --.

Arcellx has a consensus price target of $115.40, signalling upside risk potential of 95.1%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Arcellx, analysts believe Palatin Technologies is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $15.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Arcellx's net income of -$47.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, Arcellx's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 29.35x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -308.4% compared to Arcellx's net margin of -18.58%. Arcellx's return on equity of -22.3% beat Retractable Technologies's return on equity of -16.83%.

Arcellx has a consensus price target of $115.40, signalling upside risk potential of 95.1%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Arcellx has higher upside potential than Retractable Technologies, analysts believe Arcellx is more attractive than Retractable Technologies.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Arcellx quarterly revenues are $15.3M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Arcellx's net income of -$47.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Arcellx's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 29.35x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.